AstraZeneca has had a setback to its ambitions in diabetes, after Bydureon failed to show cardiovascular benefits to patients. The FDA now obliges companies with diabetes products to conduct large ...

Retatrutide is an new drug that has shown promise in the treatment of obesity and type 2 diabetes. Retatrutide is a type of multi-receptor agonist that targets multiple hormonal pathways involved in ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Keeping Toronto neighbourhoods safe is our collective responsibility. Improperly discarded needles and harm reduction supplies found in our communities have been identified as a concern. In an effort ...